Printed From BioPortfolio.com
T-cell therapies: Part 2 () - What comes after CD19 CAR?
10:19 EDT 27 Sep 2017 | Edison Investment Research
Edison Investment Research - Pharmaceutical & healthcare - T‐cell cancer therapies: This report forms Part 2 of a detailed review of T-cell therapies. It gives a more detailed and scientific overview of the area to enhance the summary analysis of investment criteria in Part 1. This report has a general technology introduction and four detailed therapy-focused sections.
Original Article: T-cell therapies: Part 2 () - What comes after CD19 CAR?
